OraSure Technologies (NASDAQ:OSUR) Upgraded at StockNews.com

StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR - Free Report) from a hold rating to a buy rating in a report published on Friday.

OraSure Technologies Trading Down 1.2 %

OSUR stock traded down $0.05 during mid-day trading on Friday, reaching $3.68. The company's stock had a trading volume of 372,827 shares, compared to its average volume of 800,762. The company's 50 day moving average is $3.82 and its two-hundred day moving average is $4.10. The stock has a market cap of $274.13 million, a PE ratio of 24.50 and a beta of 0.05. OraSure Technologies has a fifty-two week low of $3.52 and a fifty-two week high of $8.30.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to analysts' expectations of $38.97 million. During the same quarter in the previous year, the company posted $0.27 EPS. The company's revenue was down 55.2% compared to the same quarter last year. On average, analysts forecast that OraSure Technologies will post -0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Atom Investors LP acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth about $49,000. Creative Planning purchased a new position in OraSure Technologies during the third quarter worth about $54,000. Mackenzie Financial Corp acquired a new stake in shares of OraSure Technologies during the second quarter valued at about $72,000. Intech Investment Management LLC purchased a new stake in shares of OraSure Technologies in the 3rd quarter valued at approximately $84,000. Finally, SkyView Investment Advisors LLC lifted its holdings in shares of OraSure Technologies by 100.0% in the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 12,000 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.